

Please type a plus sign (+) inside this box → +


PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>Complete if Known</b>	
Application Number	09/871,441			
Filing Date	05/31/2001			
First Named Inventor	Steven J. Rychnovsky			
Group Art Unit	1614			
Examiner Name	Unknown			
Attorney Docket Number	17858/120103			

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
A	A1	5,116,864		March et al.	05/26/1992	
	A2	5,514,707		Deckelbaum et al.	05/07/1996	
	A3	5,354,774		Deckelbaum et al.	10/11/1994	
	A4	5,308,861		Aizawa et al.	05/03/1994	
	A5	6,132,423		Aita et al.	10/17/2000	
	A6	6,071,944		Rodgers et al.	06/06/2000	
	A7	5,620,438		Amplatz et al.	04/15/1997	
	A8	5,833,682		Amplatz et al.	11/10/1998	
	A9	5,964,751		Amplatz et al.	10/12/1999	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>8</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	B1		WO 01/35997		Allison, Beth et al.	05/25/2001		
	B2		WO 01/24825		Lamuraglia, Glenn, Michael et al.	04/12/2001		

Examiner Signature		Date Considered	9/3/02
--------------------	--	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard (ST.3)). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/871,441
		Filing Date	05/31/2001
		First Named Inventor	Steven J. Rychnovsky
		Group Art Unit	1614
		Examiner Name	Unknown
Sheet 3 of 3	Attorney Docket Number	17858/120103	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C12	ISAAC NYAMEKYE, et al., Photodynamic Therapy of Normal and Balloon-Injured Rat Carotid Arteries Using 5-Amino-Levulinic Acid (journal), American Heart Association, Inc., 12/15/1995, pp. 417-425, vol. 91, no. 2	
	C13	MOTOYA HAYASE, et al., Photoangioplasty With Local Motexafin Lutetium Delivery Reduces Macrophages in a Rabbit Post-Balloon Injury Model (journal), Cardiovascular Research, 2001, pp. 449-455, vol. 49	
	C14	GLENN M. LAMURAGLIA, et al., Chloroaluminum Sulfonated Phthalocyanine Partitioning in Normal and Intimal Hyperplastic Artery in the Rat, Implications for Photodynamic Therapy (journal), American Journal of Pathology, 12/28/1992, pp. 1898-1905, vol. 142, no. 6	
	C15	YUKARI YASUNAKA, et al., In Vivo Accumulation of Photosensitizers in Atherosclerotic Lesions and Blood in Atherosclerotic Rabbit (journal), Lasers in the Life Sciences, 1991, pp. 53-65	
	C16	J. P. SAVARY, et al., Photodynamic Therapy of Early Squamous Cell Carcinomas of the Esophagus: A Review of 31 Cases (journal), Georg Thieme Verlag Stuttgart, Endoscopy, 1998, pp. 258-265, vol. 30	
	C17	J. H. KINSEY, et al, Photodynamic Effect of Hematoporphyrin Derivative as a Function of Optical Spectrum and Incident Energy Density (journal), Cancer Research, 12/1981, pp. 5020-5026, vol. 41	
	C18	CancerLinksUSA, Cancer Treatment: Photodynamic Therapy (website article), 8/24/99	
	C19	DUSA Pharmaceuticals, Inc/Berlex Laboratories, Inc., Novel Therapy Receives FDA Approval for Treatment of Common Skin Lesions (website article), 9/27 <i>Publication date not available</i>	
	C20	Levulan (registered trademark) Kerastick (registered trademark) (aminolevulinic acid HCl) for Topical Solution, 20% (advertisement), 2000	

Examiner Signature		Date Considered	9/3/02
--------------------	--	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
	<b>Application Number</b>	09/871,441	
	<b>Filing Date</b>	05/31/2001	
	<b>First Named Inventor</b>	Steven J. Rychnovsky	
	<b>Group Art Unit</b>	1614	
	<b>Examiner Name</b>	Unknown	
<b>Sheet</b>	<b>2</b>	<b>of</b>	<b>3</b>
	<b>Attorney Docket Number</b>		17858/120103

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	G. MICHAEL VINCENT, et al., Effects of Benzoporphyrin Derivative Monoacid on Balloon Injured Arteries in a Swine Model of Restenosis (journal), SPIE, pp 72-77, vol. 2671 (publication date not available)	
	C2	C. A. WATERS, et al., Photodynamic Therapy with the New Photosensitizer Drug MV6401 Prevents Neointima Formation in Balloon-Injured Rat Carotid Arteries (journal), Supplement to Circulation, Abstracts from Scientific Sessions 2000, 11/12/2000, p 423, vol. 102, no. 18	
	C3	I. M. LEITCH, et al., Photodynamic Therapy with the New Photosensitizer Drug, MV6401, Results in Targeted Cell Death of Neo-Intimal Lesions in Rat Arteries (journal), Supplement to Circulation, Abstracts from the 72nd Scientific Sessions, 11/7/1999, p 247, vol. 100, no. 18	
	C4	S. G. ROCKSON, et al., Photoangioplasty: An Emerging Clinical Cardiovascular Role for Photodynamic Therapy (journal), Circulation, 08/01/2000, pp 591-596, vol. 102	
	C5	P. ORTU, et al., Treatment of Arterial Intimal Hyperplasia with Photodynamic Therapy (journal), Photodynamic Therapy and Biomedical Lasers, 1992, pp 225-232	
	C6	D. ETON, et al., Inhibition of Intimal Hyperplasia by Photodynamic Therapy Using Photofrin (journal), Journal of Surgical Research, 1992, pp 558-562, vol. 53, no. 6	
	C7	M. P. JENKINS, et al., Reduction in the Response to Coronary and Iliac Artery Injury with Photodynamic Therapy Using 5-Aminolaevulinic Acid (journal), Cardiovascular Research, 1999, pp 1-8, 1	
	C8	P. GONSCHIOR, et al., Endovascular Catheter-Delivered Photodynamic Therapy in an Experimental Response to Injury Model (journal), Basic Res Cardiol, 1997, pp.310-319, vol. 92	
	C9	G. M. LAMURAGLIA, et al., Photodynamic Therapy of Vein Grafts: Suppression of Intimal Hyperplasia of the Vein Graft But Not the Anastomosis (journal), Journal of Vascular Surgery, June 1995, vol. 21, no. 6	
	C10	G. M. LAMURAGLIA, et al., Photodynamic Therapy Inhibition of Experimental Intimal Hyperplasia: Acute and Chronic Effects (journal), Journal of Vascular Surgery, 1994, pp. 321-331, vol. 19, no. 2	
	C11	HUGH L. NARCISO, et al., Retention of Tin Ethyl Etiopurpurin (SnET2) by Atheromatous Plaques: Studies in Vitro & In Vivo Rabbit (journal), SPIE, pp. 30-41, vol. 2130 (publication date not available)	

Examiner Signature	Date Considered	9/3/02
--------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.